AR073964A1 - Composiciones que comprenden acido 4-(2-(5-bromo-4-(1-ciclopropilnaftalen -4-il) -4h- 1,2,4-triazol-3-il tio ) acetamido)-3-clorobenzoico y sus sales farmaceuticamente aceptables y metodos de preparacion y uso delos mismos - Google Patents

Composiciones que comprenden acido 4-(2-(5-bromo-4-(1-ciclopropilnaftalen -4-il) -4h- 1,2,4-triazol-3-il tio ) acetamido)-3-clorobenzoico y sus sales farmaceuticamente aceptables y metodos de preparacion y uso delos mismos

Info

Publication number
AR073964A1
AR073964A1 ARP090104095A ARP090104095A AR073964A1 AR 073964 A1 AR073964 A1 AR 073964A1 AR P090104095 A ARP090104095 A AR P090104095A AR P090104095 A ARP090104095 A AR P090104095A AR 073964 A1 AR073964 A1 AR 073964A1
Authority
AR
Argentina
Prior art keywords
subject
ciclopropilnaftalen
chlorobenzoic
triazol
acetamide
Prior art date
Application number
ARP090104095A
Other languages
English (en)
Inventor
Colin Edward Rowlings
Barry D Quart
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of AR073964A1 publication Critical patent/AR073964A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicacion 1: Una composicion farmacéutica caracterizada porque comprende un compuesto o mezcla de compuestos de estructura (1) donde M es hidrogeno, sodio, potasio, calcio, o arginina; y uno o más diluyentes; uno o más aglutinantes; uno o más agentes recubridores; uno o más agentes dispersantes; y uno o más plastificantes. Reivindicacion 16: Un método para prevenir una infeccion de un virus de inmunodeficiencia en un sujeto, para tratar una infeccion de un virus de inmunodeficiencia en un sujeto, para prevenir el síndrome de inmunodeficiencia adquirida (SIDA) en un sujeto, para tratar el síndrome de inmunodeficiencia adquirida (SIDA) en un sujeto, para prevenir el complejo relacionado con el SIDA (ARC) en un sujeto o para tratar el complejo relacionado con el SIDA (ARC) en un sujeto, caracterizado porque comprende administrarle a un sujeto que lo necesita una cantidad eficaz de una composicion de acuerdo con cualquiera de las reivindicaciones precedentes.
ARP090104095A 2008-10-24 2009-10-23 Composiciones que comprenden acido 4-(2-(5-bromo-4-(1-ciclopropilnaftalen -4-il) -4h- 1,2,4-triazol-3-il tio ) acetamido)-3-clorobenzoico y sus sales farmaceuticamente aceptables y metodos de preparacion y uso delos mismos AR073964A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10843708P 2008-10-24 2008-10-24

Publications (1)

Publication Number Publication Date
AR073964A1 true AR073964A1 (es) 2010-12-15

Family

ID=41491449

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104095A AR073964A1 (es) 2008-10-24 2009-10-23 Composiciones que comprenden acido 4-(2-(5-bromo-4-(1-ciclopropilnaftalen -4-il) -4h- 1,2,4-triazol-3-il tio ) acetamido)-3-clorobenzoico y sus sales farmaceuticamente aceptables y metodos de preparacion y uso delos mismos

Country Status (7)

Country Link
US (1) US20110244049A1 (es)
EP (1) EP2349258A1 (es)
AR (1) AR073964A1 (es)
CA (1) CA2741368A1 (es)
IL (1) IL212463A0 (es)
TW (1) TW201022215A (es)
WO (1) WO2010048593A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2433633A1 (en) 2004-08-25 2012-03-28 Ardea Biosciences, Inc. Triazolyl alpha -mercaptoacetanildes as inhibitors of HIV reverse transcriptase
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
WO2012114352A2 (en) * 2011-02-21 2012-08-30 Hetero Research Foundation Pharmaceutical compositions of maraviroc and process for the preparation thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2433633A1 (en) * 2004-08-25 2012-03-28 Ardea Biosciences, Inc. Triazolyl alpha -mercaptoacetanildes as inhibitors of HIV reverse transcriptase
WO2007050087A1 (en) * 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
CN103058944B (zh) * 2007-11-27 2015-08-05 亚德生化公司 调节血液尿酸水平的化合物

Also Published As

Publication number Publication date
IL212463A0 (en) 2011-06-30
TW201022215A (en) 2010-06-16
WO2010048593A1 (en) 2010-04-29
US20110244049A1 (en) 2011-10-06
EP2349258A1 (en) 2011-08-03
CA2741368A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
WO2008132138A9 (en) AMINOPYRIMIDINE DERIVATIVES DISUBSTITUTED IN 4 AND 6
EP2041159B8 (en) Macrocyclic compounds as antiviral agents
FI3597646T3 (fi) Hi-virusinfektion profylaktiseen tai terapeuttiseen hoitoon käyttökelpoisia terapeuttisia yhdisteitä
CL2008003431A1 (es) Compuestos derivados de nucleosidos 2',4' sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih.
RS53209B (en) PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR
CL2008003819A1 (es) Compuestos derivados del acido 2-cetoamino benzoico sustituido, inhibidores del virus de la hepatitis c; composicion farmaceutica; y su uso en el tratamiento de una infeccion por vhc.
MX2010007375A (es) Nuevos derivados de lupano.
MX2009009920A (es) Inhibidores no nucleosidos de transcriptasa inversa.
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
DK2358717T3 (da) Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes
MX2010007374A (es) Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos.
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
GEP20156368B (en) Non-nucleoside reverse transcriptase inhibitors
NO20090405L (no) Ikke-nukleoside revers transcriptase inhibitorer
MA38182A1 (fr) Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d'infections par le virus de l’immunodéficience humaine (vih)
AR067184A1 (es) Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
MX2010001338A (es) Derivados de pirimidina y piridina y su uso y composiciones farmaceuticas.
BRPI0607811B8 (pt) derivados de óxido de pirimidina de 2-(4-cianofenilamino) inibidores de hiv, composição farmacêutica compreendendo os mesmos, processo para preparar a referida composição e uso
CY1111102T1 (el) 2-(4-κυανοφαινυλ)-6-υδροξυλαμινοπυριμιδινες που αναστελλουν τον hiv
BRPI0607214B8 (pt) derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação
EA201170537A1 (ru) Ингибиторы вич-интегразы
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
AR073964A1 (es) Composiciones que comprenden acido 4-(2-(5-bromo-4-(1-ciclopropilnaftalen -4-il) -4h- 1,2,4-triazol-3-il tio ) acetamido)-3-clorobenzoico y sus sales farmaceuticamente aceptables y metodos de preparacion y uso delos mismos
MX2009010932A (es) Inhibidores no nucleosidos de transcriptasa inversa.
WO2007098247A3 (en) Substituted taraxastanes useful for treating viral infections

Legal Events

Date Code Title Description
FA Abandonment or withdrawal